BBIO vs KEY · rev $221.9M vs P/E 13, rev $7.51B
BridgeBio Pharma Inc (BBIO) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
BBIO currently screens at market cap $13.24B. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the BBIO and KEY stock pages for the full models.
Not investment advice.